$74.85
5.84% yesterday
Nasdaq, Oct 08, 10:00 pm CET
ISIN
US7207951036
Symbol
PVLA

Pieris Pharmaceuticals, Inc. Stock price

$74.85
+19.83 36.04% 1M
+54.34 264.94% 6M
+62.85 523.75% YTD
+58.81 366.61% 1Y
-9.15 10.89% 3Y
-97.95 56.68% 5Y
-73.95 49.70% 10Y
-145.15 65.98% 20Y
Nasdaq, Closing price Wed, Oct 08 2025
+4.13 5.84%
ISIN
US7207951036
Symbol
PVLA
Industry

Key metrics

Basic
Market capitalization
$782.1m
Enterprise Value
$726.2m
Net debt
positive
Cash
$70.4m
Shares outstanding
11.1m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
16.4
Financial Health
Equity Ratio
71.0%
Return on Equity
-27.2%
ROCE
-
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-37.3m
EBIT
- | $-37.3m
Net Income
- | $-37.1m
Free Cash Flow
$-14.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -166.7%
Net Income
- | -118.2%
Free Cash Flow
61.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-1.3
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is Pieris Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,997 stocks worldwide.

Pieris Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

Buy
95%
Hold
5%

Financial data from Pieris Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.65 3.65
78% 78%
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
21% 21%
-
Net Profit -22 -22
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pieris Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pieris Pharmaceuticals, Inc. Stock News

Positive
Investors Business Daily
3 days ago
Big-cap stocks like Nvidia and Palantir steal attention. But now investors are scoring gains on small caps not in the S&P 500.
Neutral
GlobeNewsWire
15 days ago
Clinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients
Positive
Seeking Alpha
17 days ago
Palvella's QTORIN rapamycin is its main value driver. This candidate is in Phase 3 trials for mLM. Management anticipates its top-line data by Q1 2026, with a potential NDA planned by 2H2026. If approved, QTORIN would be a potential first-in-disease medication, which would give it solid competitive prospects.
More Pieris Pharmaceuticals, Inc. News

Company Profile

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Head office United States
CEO Wesley Kaupinen
Founded 2001
Website palvellatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today